{"id":"14c-ly2140023","_chembl":{"chemblId":"CHEMBL375611","moleculeType":"Small molecule","molecularWeight":"235.22"},"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"mGlu2/3 receptors","explanation":"LY2140023 is a prodrug that is metabolized to the active moiety LY404039, which selectively activates metabotropic glutamate 2 and 3 (mGlu2/3) receptors. The 14C radiolabel allows tracking of drug distribution and metabolism in pharmacokinetic studies.","oneSentence":"Radiolabeled prodrug that is converted to LY404039, an agonist of metabotropic glutamate 2/3 receptors."},"_scrapedAt":"2026-03-28T06:31:40.282Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123340,"model":"claude-sonnet-4-5-20250929"},"description":"14C-LY2140023 is a radiolabeled version of LY2140023, a prodrug of the mGlu2/3 receptor agonist LY404039, developed by Denovo Biopharma. The carbon-14 labeled compound is used in Phase 1 studies to evaluate pharmacokinetics, metabolism, and drug disposition in humans.","indications":{"approved":[{"status":"investigational","condition":"Pharmacokinetic/metabolism study","patientPopulation":"Healthy volunteers or patients, Phase 1"}]},"trialDetails":[{"nctId":"NCT01637142","phase":"PHASE1","title":"A Study of LY2140023 in Healthy Participants","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2012-07","conditions":"Healthy Participants","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"14C-LY2140023","genericName":"14C-LY2140023","companyName":"Denovo Biopharma LLC","companyId":"denovo-biopharma-llc","firstApprovalDate":"","aiSummary":"14C-LY2140023 is a small molecule that acts as a metabotropic glutamate receptor 2 agonist. It was studied in a clinical trial (NCT01637142) to determine its absolute bioavailability in healthy participants.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}